Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Philip Morris gets over a fifth of Vectura shares in takeover tender offer

Published 08/18/2021, 06:26 AM
Updated 08/18/2021, 06:31 AM
© Reuters. FILE PHOTO: Philip Morris International's research and development headquarters are pictured next to the company's cigarette factory in Neuchatel, Switzerland, March 17, 2017. Picture take March 17, 2017. REUTERS/Paritosh Bansal/File Photo
PM
-
CG
-

By Siddharth Cavale

(Reuters) - Cigarette maker Philip Morris International (NYSE:PM) (PMI) said on Wednesday shareholders holding 22.61% of Vectura shares had tendered their stock to the tobacco group as part of its deal to buy the asthma drug maker for 1.1 billion pounds ($1.51 billion).

The purchase is part of a public tender offer process and comes days after PMI won the backing of Vectura's board for its 165 pence-per-share takeover offer, following a fierce bidding war against private equity firm Carlyle Group (NASDAQ:CG).

PMI, which last week switched its proposal to a takeover offer from a so-called scheme of arrangement to raise its chances, needs the backing of holders of just over 50% of Vectura shares for the deal to go through.

Health groups have raised concerns about the deal, questioning the idea of a tobacco company making money from treating the very illnesses cigarettes cause.

Smoking continues to be a leading cause of preventable deaths worldwide, according to the World Health Organization.

On Tuesday, 35 health groups, experts and anti-smoking charities, including Asthma UK and the British Lung Foundation, urged Vectura shareholders in a letter to reject the deal, citing the "business risks and the moral conflict of the proposed takeover."

The groups warned that PMI's takeover would put at risk Vectura's ability to access government grants from over 180 countries worldwide, who as part of the UN Tobacco Control Treaty have agreed to reduce the tobacco industry's influence on public health policymaking.

Vectura could also lose crucial links with academic and public health institutions and the ability to publish research in leading medical journals because of their association with a tobacco giant, the signatories said.

"We believe Vectura's future commercial viability as a company dedicated to improving respiratory health would be seriously jeopardised should the PMI takeover offer proceed," they said.

© Reuters. FILE PHOTO: Philip Morris International's research and development headquarters are pictured next to the company's cigarette factory in Neuchatel, Switzerland, March 17, 2017. Picture take March 17, 2017. REUTERS/Paritosh Bansal/File Photo

Philip Morris was not immediately available to comment on the letter.

Vectura shareholders have until Sept. 15 to decide whether to tender their shares to PMI, which is seeking to acquire the company as part of its evolution into a "smoke-free and healthcare and wellness company."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.